share_log

Arcutis Biotherapeutics | 3: Initial statement of beneficial ownership of securities-Officer Topper David Joseph

Arcutis Biotherapeutics | 3: Initial statement of beneficial ownership of securities

Arcutis Biotherapeutics | 3：首次持股声明
SEC announcement ·  04/11 20:36
Moomoo AI 已提取核心信息
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3. The filing, dated April 10, 2024, indicates that Topper beneficially owns non-derivative securities and has vested stock options in the company. Specifically, Topper has the right to buy 7,500 shares of common stock at an exercise price of $2.54 per share, with the option exercisable until December 18, 2033. The form was signed by Topper's attorney-on-fact, Masaru Matsuda, on April 11, 2024. This filing is a routine disclosure required by corporate officers to report their securities holdings in the company, in compliance with Section 16(a) of the Securities Exchange Act of 1934.
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3. The filing, dated April 10, 2024, indicates that Topper beneficially owns non-derivative securities and has vested stock options in the company. Specifically, Topper has the right to buy 7,500 shares of common stock at an exercise price of $2.54 per share, with the option exercisable until December 18, 2033. The form was signed by Topper's attorney-on-fact, Masaru Matsuda, on April 11, 2024. This filing is a routine disclosure required by corporate officers to report their securities holdings in the company, in compliance with Section 16(a) of the Securities Exchange Act of 1934.
根据表格3，Arcutis Biotherapeutics首席财务官大卫·约瑟夫·托珀已向美国证券交易委员会提交了初步的证券实益所有权声明。这份日期为2024年4月10日的文件显示，Topper以实益方式拥有非衍生证券，并已将股票期权授予该公司。具体而言，Topper有权以每股2.54美元的行使价购买7,500股普通股，该期权的行使期权有效期至2033年12月18日。该表格由托珀的实务律师松田正于2024年4月11日签署。根据1934年《证券交易法》第16（a）条，该文件是公司高管在报告其持有的公司证券时要求的例行披露。
根据表格3，Arcutis Biotherapeutics首席财务官大卫·约瑟夫·托珀已向美国证券交易委员会提交了初步的证券实益所有权声明。这份日期为2024年4月10日的文件显示，Topper以实益方式拥有非衍生证券，并已将股票期权授予该公司。具体而言，Topper有权以每股2.54美元的行使价购买7,500股普通股，该期权的行使期权有效期至2033年12月18日。该表格由托珀的实务律师松田正于2024年4月11日签署。根据1934年《证券交易法》第16（a）条，该文件是公司高管在报告其持有的公司证券时要求的例行披露。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息